drugset / Trial / NCT05329103
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Timeline
- Start
- 2022-07-11
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEEL-224 | Unknown | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | FOLF+B | Unknown | — | — |
| Background | fluorouracil | Small molecule | — | — |